AHCO Quote, Financials, Valuation and Earnings

Electromed has a net margin of -1.24% compared to AdaptHealth's net margin of 12.06%. AdaptHealth's return on equity of 5.59% beat Electromed's return on equity of 16.57%.

AdaptHealth has a consensus price target of $12.88, signalling upside risk potential of 41.8%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 82%. Given that Electromed has higher upside potential than AdaptHealth, analysts believe Electromed is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.639, which suggesting that the stock is 63.885% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $580.5M, which are larger than Electromed quarterly revenues of $15.7M. AdaptHealth's net income of -$7.2M is lower than Electromed's net income of $1.9M. Notably, AdaptHealth's price-to-earnings ratio is 15.93x while Electromed's PE ratio is 25.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.38x versus 2.97x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -1.24% compared to AdaptHealth's net margin of -14.17%. AdaptHealth's return on equity of 5.59% beat IRIDEX's return on equity of -218.69%.

AdaptHealth has a consensus price target of $12.88, signalling upside risk potential of 41.8%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 110.97%. Given that IRIDEX has higher upside potential than AdaptHealth, analysts believe IRIDEX is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.639, which suggesting that the stock is 63.885% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $580.5M, which are larger than IRIDEX quarterly revenues of $11.9M. AdaptHealth's net income of -$7.2M is lower than IRIDEX's net income of -$1.7M. Notably, AdaptHealth's price-to-earnings ratio is 15.93x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.38x versus 0.32x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -1.24% compared to AdaptHealth's net margin of -35.24%. AdaptHealth's return on equity of 5.59% beat Myomo's return on equity of -38.11%.

AdaptHealth has a consensus price target of $12.88, signalling upside risk potential of 41.8%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 194.79%. Given that Myomo has higher upside potential than AdaptHealth, analysts believe Myomo is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.639, which suggesting that the stock is 63.885% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $580.5M, which are larger than Myomo quarterly revenues of $9.8M. AdaptHealth's net income of -$7.2M is lower than Myomo's net income of -$3.5M. Notably, AdaptHealth's price-to-earnings ratio is 15.93x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.38x versus 3.09x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -1.24% compared to AdaptHealth's net margin of -77.93%. AdaptHealth's return on equity of 5.59% beat Stereotaxis's return on equity of -174.6%.

AdaptHealth has a consensus price target of $12.88, signalling upside risk potential of 41.8%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 114.29%. Given that Stereotaxis has higher upside potential than AdaptHealth, analysts believe Stereotaxis is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.639, which suggesting that the stock is 63.885% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $580.5M, which are larger than Stereotaxis quarterly revenues of $7.5M. AdaptHealth's net income of -$7.2M is lower than Stereotaxis's net income of -$5.8M. Notably, AdaptHealth's price-to-earnings ratio is 15.93x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.38x versus 6.58x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.